

Express Mail Label No.: EV 392131555 US
Date of Deposit: August 2, 2004

Attorney Docket No.: 24591-501

8-3-04

TFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Becker et al.
SERIAL NUMBER: 10/626,085 EXAMINER: Not Yet Assigned
FILING DATE: July 24, 2003 ART UNIT: 1614
FOR: SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AS NEUROKININ ANTAGONISTS

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of Cited Reference C31-C33; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24591-501. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529
Nicholas P. Triano, III, Reg. No. 36,397
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer No.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: August 2, 2004



Date of Deposit: August 2, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Becker, et al.
SERIAL NUMBER: 10/626,085 EXAMINER: Not Yet Assigned
FILING DATE: July 24, 2003 ART UNIT: 1614
FOR: SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AS NEUROKININ ANTAGONISTS

MAIL STOP Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Becker, et al.
U.S.S.N.: 10/626,085

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24591-501.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Nicholas P. Triano, III, Reg. No. 36,397
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer No.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: August 2, 2004

TRA 1944268v1



Express Mail Label: EV 392131555 US
Date of Deposit: August 2, 2004

Page 1 of 1
Attorney Docket No.: 23254-507

Please type a plus sign (+) in this box



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/626,085	
				Filing Date		July 24, 2003	
				First Named Inventor		Dhanoa	
				Group Art Unit		1614	
				Examiner Name		Not Yet Assigned	
				Attorney Docket Number		24591-501	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes No	
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C31	Database Caplus on STN, Accession Number 1999:783937, Castelhana, et al., WO/99/62518 A1, CADUE PHARMACEUTICALS CORP. (1999).					
	C32	Database Caplus on STN, Accession Number 2000:806616, Horvath, et al., 6,147,085, NEUROGEN CORPORATION (2000).					
	C33	International Search Report for PCT/US03/23539, mailing date: July 23, 2004.					

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.